Eli Lilly ($LLY) and its close diabetes drug development partner Boehringer Ingelheim laid out a slate of positive late-stage data for its diabetes treatment empagliflozin.
E&Y's report today highlighted a growing financial weakness among Big Pharma companies as Big Biotech has begun to flex its growing muscles at the deal table, but everyone expects the multinationals to continue to play the starring role when it comes to the biggest deal stories of the coming year.
Cellular Dynamics has struck a deal with AstraZeneca, agreeing to provide stem cells for AZ's drug-discovery efforts.
Amicus Therapeutics revealed its success in a small midstage study of its drug to enhance enzyme therapy in patients with the rare genetic disorder Pompe disease. On the back of the upbeat data, the biotech company's shares recovered some of the lost ground from news last month of a Phase III failure for its lead candidate.
While many of its big rivals have been wheeling and dealing over the last few years, Merck has largely been quietly focused on absorbing Schering-Plough into its global system.
The success of Dune Medical Devices and its now-FDA-approved cancer tool device has sparked rumors of buyouts or an IPO, but the company's CEO says it's planning to grow organically, commercializing MarginProbe and eyeing lucrative applications for other cancers.
About the same time Pfizer was outlicensing a chronic migraine drug to the upstart Labrys, another one of its deal teams was bringing in an orphan drug program from Waltham, MA-based Repligen.
A 10-year-old German company says it will commence with a 2013 second-quarter European rollout of a new diagnostic test for early-stage breast cancer in women.
Individuals with HIV receive greater protection against the flu when given four times the normal dose of flu vaccine, a new study shows.
As a new wave of interest in HIV therapeutic vaccines hits the biotech world, a team of Spanish researchers claims to have developed such a vaccine that temporarily halts growth of the HIV virus in patients.